

## **DIABETIC RETINOPATHY (DME) AND AGE-RELATED MACULAR DEGENERATION (AMD)**


Good practices in financing mechanisms of ophthalmology: experience of Poland, Czech Republic, Slovakia and Hungary







number of people who received services for DME per 100,000 population



out treatments (PL, CZ, SK)

\*Since 2018, there is no statistical information on the prevalence and morbidity, as the order of the Ministry of Health of Ukraine No. 801802 dated 04.10.2018 cancelled the reporting form No. 12 "on the total number of diseases registered in particular medical facility and on patients with diseases for which dispensary supervision is carried out"

> only in a specialized centre (PL, CZ, SK) Introduction of financial products for evaluation of achieved outcomes for Each injection paid for AMD (PL) patient separately (HU, PL, CZ, SK) GOOD Increase quality **PRACTICES** Permission to use Avastin "off label" (SK) Specialized centres to carry



Financial products for outpatient treatment (PL)

Wide coverage of diagnostics for

DME (HU, PL, CZ)

good practice that has been supported for priority implementation

**Increase volumes** 

good practice that has been supported, but the implementation of which is postponed

good practice that is currently not being considered for implementation in Ukraine

HU - HUNGARY, PL - POLAND, CZ - CZECH REPUBLIC, SK - SLOVAKIA









The biological treatment

anti-VEGF can be applied

